

SGN-B6A

An investigational antibody-drug conjugate directed to integrin beta-6

Anti-IB6 antibody


Monoclonal antibody directed to IB6

MMAE

Microtubule-disrupting agent

Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody, which enables preferential release of MMAE within target cells.¹



Target: IB6

- Cell surface receptor that promotes cellular adhesion through interactions with the extracellular matrix, which plays a major role in solid tumor pathogenesis and invasiveness^{2,3}
- Expression is normally low but is highly upregulated during pathogenesis⁴⁻⁶
- Expressed in numerous solid tumors including NSCLC, HNSCC, esophageal cancer, cSCC, colorectal, gastric, breast, and cervical cancers^{1,7-12}
- A proposed negative prognostic marker based on multiple analyses^{9,13}

Proposed Mechanism of Action^{14-16,a}


- Direct cytotoxicity
- Bystander effect
- Immunogenic cell death

cSCC: cutaneous squamous cell carcinoma; **HNSCC:** head and neck squamous cell carcinoma; **IB6:** integrin beta-6; **mc-vc:** maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E; **NSCLC:** non-small cell lung cancer

^aBased on preclinical data


1. Lyon RP. Mol Cancer Ther. 2023: MCT-22-0817. 2. Harisi R. Onco Targets Ther. 2015: 1387-98. 3. Rathinam R. Cancer Metastasis Rev. 2010: 223-37. 4. Desgrosellier JS. Nat Rev Cancer. 2010: 9-22. 5. Bandyopadhyay A. Curr Drug Targets. 2009: 645-52. 6. Brzozowska E. Int J Mol Sci. 2022: 12346. 7. Koopman Van Aarsen LA. Cancer Res. 2008: 561-70. 8. Bengs S. Int J Cancer. 2019: 678-85. 9. Elayadi AN. Cancer Res. 2007: 5889-95. 10. Zhang ZY. Clin Oncol. 2008: 61-6. 11. Hazelbag S. J Pathol. 2007: 316-24. 12. Marsh D. Cancer Res. 2008: 3295-303. 13. Elez E. Ann Oncol. 2015: 132-40. 14. Burton JK. AAPS J. 2019: 12. 15. Lyon RP. SITC 2022: Poster 1186. 16. Trang VH. AACR 2023: Poster 1522.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Proposed Mechanism of Action^{1-4,a}

- 1 Binds to IB6
- 2 Complex internalization and trafficking
- 3 MMAE release
- 4 Microtubule disruption
- 5 Cell cycle arrest and apoptotic cell death




IB6: integrin beta-6; **MMAE:** monomethyl auristatin E

^aBased on preclinical data

^bAdditional mechanisms of action and their potential to complement the direct cytotoxicity of some MMAE-based antibody-drug conjugates are currently under investigation.

- 1. Lyon RP. Mol Cancer Ther. 2023: MCT-22-0817. 2. Burton JK. AAPS J. 2019: 12. 3. Lyon RP. SITC 2022: Poster 1186.
- 4. Trang VH. AACR 2023: Poster 1522.

Clinical Trials



Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com